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A novel gain-of-function mutation of Piezo1 is 
functionally affirmed in red blood cells by 
high-throughput patch clamp
Piezo1 is a mechanosensitive ion channel that is
believed to be expressed in red blood cells (RBCs), mainly
supported by the findings that mutations of the PIEZO1
gene are associated with the RBC disease hereditary
xerocytosis.1,2 So far, several mutations (e.g. R2456H,
T2127M and E2496ELE) have been reported to exhibit a
partial gain-of-function phenotype with generation of
mechanically activated currents that inactivate more
slowly than wild type.1-5 However, characterization of
the mutated ion channel has almost exclusively been per-
formed based on heterologous expression in cell lines,
and recordings in RBCs were only occasional.6 Here, we
present a patient with a novel PIEZO1 mutation
(R2110W) and a patch clamp based high-throughput
screening assay for Piezo1 activity. It is the first electro-
physiological single-cell based screening ever performed
on RBCs, demonstrating the Piezo1 gain-of-function
mutation directly on RBCs. Thus, we provide a putative
routine approach for detecting functional (Piezo1) chan-
nel mutations as the molecular cause of rare anaemia that
can offer a standard method in specialized hematologic
centers.
The patient, an Italian man, born from unrelated par-
ents, with no evidence of jaundice, anemia,
splenomegaly, or gallstones, was studied at the age of 43
years for compensated hemolysis and evidence sugges-
tive of iron overload. Patient’s data are summarized in
Online Supplementary Table S1. Due to abnormal RBC
morphology, characterized by presence of stomatocytes
(Figure 1A) and the observation of a marked leftward
shift osmotic gradient ektacytometry (LoRRca Osmoscan
curve evaluation, Mechatronics, Hoorn, the Netherlands)
(Figure 1B), a mild form of hereditary dehydrated stoma-
tocytosis was suspected. After receiving the patient’s
informed consent, the DNA sample of the patient was
analyzed on a next-generation sequencing (NGS)-target-
ed panel containing 40 genes associated with congenital
hemolytic anemia (see Online Supplementary Appendix and
Online Supplementary Table S2 for details). A PIEZO1
c.6328C>T missense mutation, R2110W, was identified
as  the only  causative mutation (Figure 1C and D). The
new variant (rs776531529) had not previously been
reported, minor allele frequency (MAF) was not available
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Figure 1. A novel mutation of PIEZO1
(R2110W). (A) Patient red blood cell
(RBC) peripheral blood smear (100x
objective); arrows indicate stomato-
cytes. (B) LoRRca Osmoscan profile of
the patient (dotted line), daily normal
control (black line), compared with 150
normal controls (gray area). (C)
Schematic representation of the
PIEZO1 gene and position of R2110W
mutation. Exons in which mutations
have already been reported are indi-
cated in pink. (D) Schematic represen-
tation of Piezo1 channel, orange areas
represent regions affected by muta-
tions already reported. (E, left panel)
Structural illustration of the mPiezo1
channel based on pdb file 5Z108 indi-
cating the trimeric structure of the pro-
tein from top view. (E, right panel)
Residue R2126 corresponding to
R2110 in humans is highlighted in yel-
low. It is located in the ‘anchor’ region,
that together with ‘beam’ are thought
to transmit membrane tension-induced
conformational changes into channel







Figure 2. Assay development to investigate Piezo1 activity based on activation with Yoda1. Piezo1 channels endogenously expressed in Neuro2A cells were
investigated on the SyncroPatch 384PE. (A) Screenshot of the data acquisition and analysis software of the SyncroPatch 384PE. (Upper left) Display of 384
parallel recordings, color-coded based on seal resistance (green: >500 MΩ, blue: 50 - 500 MΩ, gray: <50 MΩ or disabled). At the end of the experiment, 178
out of 384 patches (46.4%) exceeded 1 GΩ, and 87 out of 384 patches (22.7%) exceeded 3 GΩ. (Bottom center) Raw data trace of a single well recorded in
external solution (black trace) and in the presence of 10 mM Yoda1 (red trace). Currents were elicited at room temperature by a 300 ms ramp voltage protocol
from -100 to 80 mV, at a holding potential of -60 mV. The red and green vertical cursors in the trace indicate the regions of interest for the analysis, respectively
currents at -100 mV and 80 mV. (Right) Raw data traces of 16 selected wells. (B) Statistical analysis of the currents at -100mV (left) and at 80 mV (right). 140
out of 384 Neuro2A cells (37%) passed the quality criteria and 85 cells (60% of the valid cells) were considered as Yoda1 responders. The current amplitudes
did not show a Gaussian distribution and were, therefore, presented as median and box plots (25-75%) with whiskers (10-90%). There was a highly significant
increase (P<0.0001; Mann-Whitney test) whenever 10 mM Yoda1 was applied in both Yoda1-responding cells and the entire cell population at membrane
potentials of 80 mV and -100 mV. (C) Transfer of the assay to human red blood cells (RBC) and investigation of a putative Gardos channel contribution to the
Yoda1-activated current in RBC. Currents were recorded before and after 10 mM Yoda1 addition and two different experiments were conducted, respectively,
in the absence and presence of 500 nM TRAM-34, a specific Gardos channel blocker. At positive membrane potentials, there was no significant change
induced by TRAM-34, whereas at negative membrane potential, there was a slight significant increase in the absolute current amplitude. Since this change is
opposite to a putative contribution of the Gardos channel, a participation of the Gardos channel to the measured currents can be excluded.
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Figure 3. Current response of patient cells
with the novel PIEZO1 mutation (R2110W)
compared to healthy red blood cells (RBCs).
(A) Raw data traces of Piezo1 activation by
Yoda1 (red traces) recorded at room tempera-
ture in exemplary control (left) and patient
(right) RBCs. The gray bars depict the time
points (equal to membrane potential) at which
the analyzed currents were measured. (B)
Scatter charts comparing Yoda1 responder
cells in control and patient conditions. In con-
trol condition, 61 out of 301 RBCs (20% of the
valid cells) were considered as Yoda1 respon-
ders. In patient condition, 97 out of 212 (46%
of the valid cells) were considered as Yoda1
responders. Peak current amplitude values
were recorded for each cell in control and
patient conditions before and after Yoda1
administration. (C) Statistical analysis of all
measured cells, independent of their response
to Yoda1. The voltage protocol was the same
as described in Figure 2A, except the holding
potential was set to -30 mV. Because the cur-
rent amplitudes did not show a Gaussian dis-
tribution, they were presented as median and
box plots (25-75%) with whiskers (10-90%) in
patient cells compared to controls. The num-
bers adjacent to the boxes refer to the num-
bers of cells measured. Here analysis of posi-
tive 80 mV membrane potential is shown
exclusively. The analysis at negative mem-
brane potentials reveals the same results and
is depicted in Online Supplementary Figure
S1A. The baseline values (left) were already
indicating a highly significant difference
between patient and control. This difference
persisted after application of Yoda1, when
considering both Yoda1-responding cells and
the entire cell population at membrane poten-
tials of 80 mV and -100 mV. (D) Statistical
analysis of cells 3 days after blood withdrawal.
Shipped control day3 Yoda1 responders=15;
patient R2110W day3 Yoda1 responders=19;
shipped control day3 all cells=89; patient
R2110W day3 all cells=98; patient R2110W
day1 all cells=212. The difference between











with either  EXAC and 1000G, and it was predicted to be
pathogenetic by in silico analysis as deleterious by
PolyPhen2 (score 0.990) and SIFT (score 0.00), and as
possibly damaging by M-CAP (score 0.847). The same
variant has been recently reported within a series of
hemolytic patients studied by NGS but lacking functional
information.7 Residue R2110 is located in the ‘anchor’
region (Figure 1E) that together with ‘beam’ are thought
to transmit membrane tension-induced conformational
changes into channel gating by lever-like motions.8
Although it has been shown that single mutations can
interfere with channel gating transitions,2 further investi-
gations are required to elucidate the underlying structural
mechanism of this mutation.
The finding of a new mutation always raises the ques-
tion as to whether there is a functional impairment of the
affected proteins. This is particularly true in the case of
PIEZO1 mutations where a large number of VUS (vari-
ants of unknown significance) is observed. For chan-
nelopathies in general, like cystic fibrosis, erythromelal-
gia or hereditary xerocytosis, the patch clamp technique
is the most direct method to test channel activity.
However, due to the difficulties in patch clamping RBCs,9
the characterization of channelopathies effecting RBCs
has not often been reported.6 Here, we present the first
development of a high-throughput patch clamp assay for
RBCs, based on a 384-well planar patch clamp approach
(SyncroPatch 384PE, Nanion Technologies, Munich,
Germany), which goes significantly beyond our previous
work that first showed the suitability of planar patch
clamp for RBC measurements.9,10  We developed the high-
throughput assay to record Piezo1 activity in RBCs upon
chemical activation using Yoda1,11 as low abundance of
Piezo1 in RBCs requires large sample sizes and reliable
channel activation for high assay validity. Initial assay
development was performed on mouse neuroblastoma
cells (Neuro2A) due to larger abundance of Piezo1 in
these cells (Figure 2A). The experimental procedures are
described in the Online Supplementary Appendix (see
Online Supplementary Table S3 for the quality criteria
applied and Online Supplementary Figure S1 for the results
of their implementation). This strict quality filtering pro-
vided the basis on which to divide the Piezo1 response
upon Yoda1 from Neuro2A cells into Yoda1 responders
and non-responders, reflecting the biological variability
of Piezo1 currents expressed in Neuro2A cells (Figure
2A).
The assay was then transferred to RBCs (Figure 2B and
Online Supplementary Figure S1). Previous reports
described a direct activation of the Gardos channel con-
secutive to RBC mechanical stimulation, likely to be
associated with the activation of Piezo1.12 Given this, we
tested whether the assay measures Gardos channel activ-
ity instead of or in addition to Piezo1 openings.
Comparing measurements in the presence and absence of
the Gardos channel inhibitor TRAM-34 did not support
this: TRAM-34 neither decreased the recorded current at
positive nor at negative membrane potentials (Figure 2B),
excluding an involvement of Gardos channel activity in
the assay. Likewise for the RBCs, we applied strict quality
criteria and set higher seal resistance thresholds (Online
Supplementary Table S3) in order to separate Yoda1
responders from non-responders (Online Supplementary
Figure S1). This indicates the importance of recording a
large number of cells to allow for a thorough statistical
analysis. However, utilizing the SyncroPatch 384/768PE
(Nanion Technologies, Munich, Germany) and consider-
ing the quality criteria and success rate (Online
Supplementary Table S3 and Online Supplementary Figure
S1), one or two runs of the assay, corresponding to a time
of 20-40 minutes, are sufficient to obtain statistical data
on more than 100 RBCs. It is worthwhile to notice that
manual patch clamp would require 2 weeks of continu-
ous lab work, which would not meet the requirement to
work on ‘fresh’ cells (see below).
Finally, we characterized the electrophysiological prop-
erties from healthy and patient RBCs carrying the novel
PIEZO1 R2110W mutation (Figure 3A). Please note that
Figure 3B contains exclusively responding cells, while the
statistics in Figure 3C contain all cells meeting the quality
criteria depicted in Online Supplementary Table S3, inde-
pendent of their response to Yoda1. The higher current
amplitude at positive potentials compared to negative
ones can be clearly explained by the recently reported
voltage dependence of Piezo1.13 A highly significantly
increased whole-cell current (P<0.0001; Mann-Whitney
test) was identified for baseline currents and Yoda1-
induced currents, considering both Yoda1-responding
cells and the entire cell population at membrane poten-
tials of 80 mV (Figure 3C) and -100 mV (Online
Supplementary Figure S2A). The percentage of RBCs
responding to Yoda1 is higher in the patient (46%) than
the control (20%), probably due to an augmented cationic
non-selective permeability of Piezo1-mutated RBCs.
Although there is a significant difference between control
and patient RBCs already at baseline conditions (Figure
3C, left), this difference is hardly indicative of a specific
mutation. Only the differences after application of Yoda1
can account for differences in Piezo1 activity. In line with
previous reports of PIEZO1mutations in RBCs,1-5 and con-
sidering both baseline currents and Yoda1-induced cur-
rents (Figure 3), also R2110W represents a gain-of-func-
tion mutation. The structural localization of the residue in
a gating-sensitive region of the channel protein would
support this hypothesis. Our high-throughput patch
clamp assay allows such evidence to be understand direct-
ly from RBC performed patch clamp recordings without
the need to generate heterologously over-expressing cell
lines. Heterologous studies represent a valuable method
to assess amino acid changing variants in polymorphic
proteins such as Piezo1. However, investigating heterolo-
gous cell lines is expensive and time consuming. Our
approach is suited to characterize the functional electro-
physiological impairment of RBCs from hereditary xero-
cytosis patients in less than 30 min, presenting a useful
complementation of gene sequencing. We like to stress
that we noticed a disappearance of the difference in the
Yoda1-induced current over time (within 3 days) in stor-
age (Figure 3D). Thus assays are recommended to be per-
formed in laboratories, where samples can be processed
within 24 hours after blood withdrawal. 
Patch clamp based screening assays may extend to
other RBC-related channelopathies, like Gardos
Channelopathy10 or hereditary anemias that present an
increased channel activity as a secondary effect, like
NMDA-receptor activity in sickle cell disease.14 This is of
particular importance since membrane leak of Ca2+,
which is mostly mediated by ion channels, was proposed
to be a common component in the molecular regulation
of anemias.15 However, due to the technical investment
required, such patch clamp assays might be limited to
application in research laboratories or hematologic cen-
ters.
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